Cetuximab-opsonized A431 cells, as well as trastuzumab-opsonized A431 cells, demonstrated enhanced neutrophil-dependent tumor killing in response to CD47-SIRPα inhibition (152, 173). Here, CD47 is linked to neoplasm.